LncRNA‐mediated posttranslational modifications and reprogramming of energy metabolism in cancer
YT Tan, JF Lin, T Li, JJ Li, RH Xu… - Cancer …, 2021 - Wiley Online Library
Altered metabolism is a hallmark of cancer, and the reprogramming of energy metabolism
has historically been considered a general phenomenon of tumors. It is well recognized that …
has historically been considered a general phenomenon of tumors. It is well recognized that …
SARS: epidemiology
M Chan‐Yeung, RH Xu - Respirology, 2003 - Wiley Online Library
Severe acute respiratory syndrome (SARS) originated in Southern China in November 2002,
and was brought to Hong Kong in February 2003. From Hong Kong, the disease spread …
and was brought to Hong Kong in February 2003. From Hong Kong, the disease spread …
Gastric cancer treatment: recent progress and future perspectives
WL Guan, Y He, RH Xu - Journal of hematology & oncology, 2023 - Springer
Gastric cancer (GC) is one of the most common malignancies worldwide. Most patients are
diagnosed at advanced stages due to the subtle symptoms of earlier disease and the low rate …
diagnosed at advanced stages due to the subtle symptoms of earlier disease and the low rate …
Circulating tumour DNA methylation markers for diagnosis and prognosis of hepatocellular carcinoma
An effective blood-based method for the diagnosis and prognosis of hepatocellular carcinoma
(HCC) has not yet been developed. Circulating tumour DNA (ctDNA) carrying cancer-…
(HCC) has not yet been developed. Circulating tumour DNA (ctDNA) carrying cancer-…
Current cancer situation in China: good or bad news from the 2018 Global Cancer Statistics?
RM Feng, YN Zong, SM Cao, RH Xu - Cancer communications, 2019 - Wiley Online Library
Cancer is the leading cause of death in China and depicting the cancer pattern of China
would provide basic knowhows on how to tackle it more effectively. In this study we have …
would provide basic knowhows on how to tackle it more effectively. In this study we have …
The Chinese Society of Clinical Oncology (CSCO): Clinical guidelines for the diagnosis and treatment of gastric cancer, 2021
…, SX Rao, Y Xin, WQ Sheng, HM Xu… - Cancer …, 2021 - Wiley Online Library
There exist differences in the epidemiological characteristics, clinicopathological features,
tumor biological characteristics, treatment patterns, and drug selections between gastric …
tumor biological characteristics, treatment patterns, and drug selections between gastric …
DNA methylation markers for diagnosis and prognosis of common cancers
The ability to identify a specific cancer using minimally invasive biopsy holds great promise
for improving the diagnosis, treatment selection, and prediction of prognosis in cancer. Using …
for improving the diagnosis, treatment selection, and prediction of prognosis in cancer. Using …
Toripalimab or placebo plus chemotherapy as first-line treatment in advanced nasopharyngeal carcinoma: a multicenter randomized phase 3 trial
…, C Hu, K Yang, J Wen, J Li, YR Shi, F Jin, R Xu… - Nature medicine, 2021 - nature.com
Gemcitabine-cisplatin (GP) chemotherapy is the standard first-line systemic treatment for
recurrent or metastatic nasopharyngeal carcinoma (RM-NPC). In this international, double-blind…
recurrent or metastatic nasopharyngeal carcinoma (RM-NPC). In this international, double-blind…
Toripalimab plus chemotherapy in treatment-naïve, advanced esophageal squamous cell carcinoma (JUPITER-06): A multi-center phase 3 trial
…, Z Chen, D Jiang, Q Lin, W Ren, J Wang, L Wu, Y Xu… - Cancer cell, 2022 - cell.com
Platinum-based chemotherapy is the standard first-line treatment for advanced esophageal
squamous cell carcinoma (ESCC). In this phase 3 study (ClinicalTrial.gov: NCT03829969), …
squamous cell carcinoma (ESCC). In this phase 3 study (ClinicalTrial.gov: NCT03829969), …
Perioperative toripalimab and chemotherapy in locally advanced gastric or gastro-esophageal junction cancer: a randomized phase 2 trial
…, JB Li, XW Tang, JS Peng, ZW Zhou, RH Xu… - Nature medicine, 2024 - nature.com
Perioperative chemotherapy is the standard treatment for locally advanced gastric or gastro-esophageal
junction cancer, and the addition of programmed cell death 1 (PD-1) inhibitor is …
junction cancer, and the addition of programmed cell death 1 (PD-1) inhibitor is …